Editor/NN
's/POS
Introduction/NN
to/TO
This/DT
Issue/NN
./.
====================
Recently/RB
,/,
next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
technologies/NNS
have/VBP
become/VBN
the/DT
most/JJS
important/JJ
part/NN
of/IN
genetic/JJ
testing/NN
to/TO
understand/VB
life/NN
phenomena/NNS
and/CC
disease/NN
mechanisms/NNS
./.
====================
As/IN
one/CD
of/IN
the/DT
important/JJ
moves/NNS
towards/IN
personalized/VBD
medicine/NN
,/,
NGS/NN
technology/NN
is/VBZ
being/VBG
rapidly/RB
introduced/VBD
to/TO
the/DT
clinical/JJ
field/NN
./.
====================
However/RB
,/,
considering/VBG
the/DT
cost/JJ
and/CC
time/NN
for/IN
the/DT
analysis/NN
after/IN
sequencing/NN
per/IN
se/FW
,/,
whole-genome/DT
or/CC
whole-exome/JJ
sequencing/NN
might/MD
not/RB
be/VB
the/DT
most/JJS
efficient/JJ
genetic/JJ
testing/NN
methods/NNS
yet/RB
./.
====================
Regarding/VBG
this/DT
issue/NN
,/,
Dr./NNP
Byung/JJ
Chul/JJ
Kim/NN
's/POS
group/NN
,/,
Theragen/NN
Bio/NNP
Institute/JJ
,/,
reports/NNS
a/DT
fast/JJ
and/CC
cost-effective/JJ
NGS/NN
method/NN
to/TO
identify/VB
somatic/JJ
mutations/NNS
in/IN
lung/NN
cancer/NN
./.
====================
They/PRP
chose/NN
30/CD
genes/NNS
potentially/RB
associated/VBN
with/IN
lung/NN
cancer/NN
development/NN
,/,
performed/VBN
target/NN
gene/NN
capture/NN
,/,
and/CC
analyzed/VBD
the/DT
findings/NNS
by/IN
NGS/NN
./.
====================
This/DT
approach/NN
could/MD
be/VB
useful/JJ
for/IN
detecting/VBG
well-known/JJ
key/JJ
mutations/NNS
as/IN
well/RB
as/IN
novel/JJ
variants/NNS
in/IN
lung/NN
cancer/NN
./.
====================
Dr./NNP
Hyung/JJ
Doo/NN
Shin/NN
's/POS
group/NN
,/,
Sogang/NNP
University/NN
,/,
hypothesized/VBN
that/IN
polymorphisms/NNS
in/IN
the/DT
tyrosine-protein/JJ
kinase/NN
Tec/JJ
,/,
which/WDT
is/VBZ
involved/VBN
in/IN
various/JJ
immune/JJ
responses/NNS
,/,
might/MD
be/VB
involved/VBN
in/IN
aspirin-exacerbated/JJ
respiratory/JJ
disease/NN
pathogenesis/NN
./.
====================
Although/IN
they/PRP
did/VBD
not/RB
observe/VB
a/DT
positive/JJ
association/NN
,/,
this/DT
study/NN
can/MD
help/VB
us/PRP
understand/VB
the/DT
genetic/JJ
component/NN
of/IN
this/DT
condition/NN
./.
====================
Dr./NNP
Dorairaj/NNP
Sudarsanam/NN
's/POS
group/NN
,/,
Loyola/NNP
College/NN
,/,
India/NN
,/,
reported/VBD
the/DT
results/NNS
of/IN
their/PRP$
exploration/NN
of/IN
the/DT
Gm18/NN
and/CC
m1G37/NN
modification/NN
positions/NNS
in/IN
tRNA/NN
sequences/NNS
./.
====================
Dr./NNP
Satish/JJ
Kumar/JJ
's/POS
group/NN
,/,
Mahatma/NNP
Gandhi/NNP
Institute/JJ
of/IN
Medical/JJ
Sciences/NNS
,/,
India/NN
,/,
suggested/VBD
the/DT
molecular/JJ
interaction/NN
of/IN
natural/JJ
inhibitors/NNS
with/IN
the/DT
human/JJ
papillomavirus-16/NN
E6/NN
oncoprotein/NN
./.
====================
In/IN
the/DT
application/NN
note/NN
section/NN
,/,
Dr./NNP
Dong/JJ
Su/NN
Yu/NN
's/POS
group/NN
,/,
KOBIC/NN
,/,
reports/NNS
a/DT
simple/JJ
and/CC
fast/JJ
protein/NN
function/NN
annotation/NN
system/NN
,/,
named/VBN
SFannotation/NN
./.
====================
Genomics/NNS
&/CC
Informatics/NNS
is/VBZ
already/RB
available/JJ
in/IN
PubMed/JJ
Central/JJ
and/CC
PubMed/JJ
./.
====================
Taking/VBG
these/DT
efforts/NNS
together/RB
,/,
we/PRP
expect/VBP
broader/JJR
international/JJ
visibility/NN
of/IN
Genomics/NNS
&/CC
Informatics/NNS
./.
====================
